Immortagen Completes Series A Financing for Personalized Medicine

- September 19th, 2016

Immortagen, Inc. announced that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen’s product pipeline fills a key gap as more … Continued

Immortagen, Inc. announced that it has successfully completed its Series A financing.  Immortagen is a cutting edge cancer company that is developing genetic analysis tools for personalized medicine.  These proprietary tools will assist pharmaceutical and diagnostics companies to interpret next-generation genetic data and guide clinical trial design and recruitment.  Immortagen’s product pipeline fills a key gap as more and more patient tumors are sequenced, and genetic analysis of the data is required.  Founded by a team of leading physician-researchers and complemented with proven management, Immortagen believes it will fill a key gap in the global oncology market.
Related Files


ImmortaPressFinl for Series A 8-1-16-1-2.docx
This content was issued through the press release distribution service at Newswire.com. For more info visit: http://www.newswire.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immortagen-inc-completes-series-a-financing-for-personalized-medicine-300330524.html
SOURCE Immortagen, Inc.

Leave a Reply